Surfactant replacement therapy is now an integral part of the care of neonates since several clinical trials of natural surfactant extracts and synthetic preparations have shown efficacy in the treatment of infants with hyaline membrane disease. In these studies, early treatment with exogenous surfactant substantially reduced mortality and the incidence of air leak, although it did not appear to reduce the incidence of other complications, in particular bronchopulmonary dysplasia. Early reports of exogenous surfactant therapy in patients with the adult respiratory distress syndrome, although promising, remain limited in number. More research is needed to improve on current modes of therapy and to investigate the possible role of surfactant in other lung diseases of both newborns and adults.
|Original language||English (US)|
|Number of pages||8|
|Journal||Western Journal of Medicine|
|State||Published - 1995|
ASJC Scopus subject areas